Medindia

X

Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results

Wednesday, November 7, 2007 General News J E 4
Advertisement
WAKEFIELD, MA, Nov. 6 /PRNewswire-FirstCall/ - NUCRYST PharmaceuticalsCorp. will hold a webcast at 4:30 p.m. EST on Wednesday, November 7, 2007regarding the company's 2007 third quarter results.

In addition to standard disclosure over wire services, a news release andfinancial statements will be posted on the NUCRYST web site. To listen to thecall live on the Internet, please go to www.nucryst.com.

Thomas E. Gardner, Chairman, President & CEO and Eliot M. Lurier, VicePresident, Finance & Administration and Chief Financial Officer willparticipate on the call.

An audio file of the call will be archived and posted on the NUCRYST website.

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufacturesand commercializes medical products that fight infection and inflammationusing its patented atomically disordered nanocrystalline silver technology.Smith & Nephew plc sell a range of advanced wound care products under theirActicoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST'sSILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is alsodeveloping pharmaceutical products to address medical conditions that arecharacterized by both infection and inflammation. The Company has developedits proprietary nanocrystalline silver in a powder form for use as an activepharmaceutical ingredient, referred to as NPI 32101.

SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

Acticoat(TM) is a trademark of Smith & Nephew plc

SOURCE NUCRYST Pharmaceuticals Corp.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Kingfisher Announces 510(k) Submission to FDA for ...
S
China Aoxing Pharmaceutical Will Present at the Th...